TO THE EDITOR
Nishii et al 1 have recently described a minor subset of acute myeloid leukemia (AML) patients with t(8;21) and trisomy 4, who had a relatively poor prognosis when compared to t(8;21) AML patients with or without other cytogenetic abnormalities. A review of the literature suggests a possible mechanism for this poor prognosis. Current theory regarding the pathogenesis of AML, especially in those patients with either a t(8;21)(q22;q22) or inv(16)(p13q22) abnormality, has postulated the cooperativity of core-binding factor (CBF) gene rearrangements (AML1-ETO and CBFB-MYH11, respectively) with mutations in those genes encoding receptor tyrosine kinases (eg FLT3, KIT). 2 In particular, mutations of the c-kit gene, located at chromosome 4q11-q12, have been detected in a significant proportion of patients with CBF-AML 3 and also in two patients with t(8;21) and trisomy 4. 4 In one of these latter patients, the trisomy 4 lead to duplication and thus increased dosage of the mutated c-kit allele, 5 suggesting an additional mechanism of leukemogenesis. This observation is supported by evidence of amplification of a c-kit mutation in the t(8;21) and trisomy fourpositive cell line Kasumi-1. 6 Further investigation is therefore warranted to determine the presence of c-kit mutations in the three t(8;21) AML patients with trisomy 4 described by Nishii et al, 1 as the most common activating mutation of c-kit has been show to confer drug resistance, 7 which could be partly responsible for the relatively poor prognosis. If mutations are present, these patients may be eligible for additional treatment with novel therapies that inhibit KIT tyrosine kinase activity. TO THE EDITOR Dr. Langabeer and his colleagues made several interesting suggestions in discussing our recent paper. 1 Our work showed that t(8;21) acute myeloid leukemia (AML) with trisomy 4 had different morphology, phenotype, and clinical outcome when compared to t(8;21) AML with or without other chromosomal abnormalities, especially t(8;21) AML plus trisomy 4 having a poor prognosis. Dr. Langabeer et al, speculate that the presence of c-kit mutation in the t(8;21) AML patients with trisomy 4 may have caused these events. It had been reported that c-kit mutations were more frequently observed in core binding factor leukemia. 2, 3 Among these c-kit mutations, mutation of codon 816 (most commonly Asp816Val) of the c-kit caused constitutive activation of the KIT kinase 4,5 and had been shown to confer drug resistance. 6,7 Therefore, we examined for c-kit mutation in a t(8;21) AML with trisomy 4 sample among those reported by Nishii et al, 1 only one sample was available for analysis. Mutation screening was targeted on exon 17 at codon 816 (amino acid 2468) of c-kit. cDNA was amplified using reverse transcription-polymerase chain reaction (RT-PCR) method and amino-acid sequence was investigated as described previously. 8, 9 As shown in Figure 1 , the presence of the Asp816Val mutation was detected in leukemic cells from this sample. Beghini et al 10,11 also reported the mutation of codon 816 of c-kit gene in two cases of t(8;21) AML with trisomy 4. These observations led us to speculate that an activating mutation of c-kit may be associated with t(8;21) AML with trisomy 4, perhaps this additional aberration could have caused the poor prognosis. To confirm the relationship between Correspondence: Dr K Nishii, Fax: +81 59 231 5200
